Group 1 - Investment Rating: Buy [2] - Core Logic: Tianyi Medical, a leading manufacturer of blood purification consumables in China, has strategically acquired to complete the CRRT (Continuous Renal Replacement Therapy) product matrix, establishing a complete ecosystem of "equipment + consumables + services" [5][6] - Expected Performance Growth: The company is anticipated to achieve rapid performance growth driven by the continuous increase in ESRD (End-Stage Renal Disease) patients, policy benefits, and expansion into overseas markets [5][6] Group 2 - Industry Demand: The number of ESRD patients in China is projected to grow from 4.12 million in 2023 to 5.27 million by 2027, with a CAGR of 6.32% from 2023 to 2027, indicating a significant market opportunity [6][15] - Market Expansion: The blood dialysis market in China is expected to reach 51.515 billion yuan by 2030, driven by increasing patient awareness, improved healthcare policies, and advancements in blood purification technologies [6][15] - Treatment Rate: The treatment rate for ESRD patients in China remains low at 24.40%, significantly below developed countries, indicating room for growth in the market [15][46] Group 3 - Business Structure: The company has established three main business pillars: blood purification consumables, CRRT, and ward care, enhancing its competitive advantage through both organic growth and acquisitions [7][8] - Strategic Partnerships: A strategic cooperation with Fresenius Medical is expected to accelerate the growth of the blood purification consumables business, with an estimated first-year supply contract worth 40 million USD starting in 2026 [7][16] - Acquisition Strategy: The company has completed acquisitions to solidify its CRRT product line, becoming one of the few companies globally with a full range of CRRT products, which will enhance its operational capabilities [8][18] Group 4 - Revenue Forecast: The company expects revenues of 514 million yuan, 936 million yuan, and 1.556 billion yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 22.7%, 82.1%, and 66.3% [9][11] - Net Profit Projection: The projected net profits for 2025, 2026, and 2027 are 21 million yuan, 96 million yuan, and 234 million yuan, with significant year-on-year growth rates of 2967.9%, 350.4%, and 143.3% [9][11] - Valuation Metrics: The price-to-earnings (P/E) ratios for 2025, 2026, and 2027 are expected to be 162, 36, and 15 times respectively, indicating a favorable investment outlook [10][11]

S1500523080002 S1500524120003 S1500523080011 tangaijin@cindasc.com Hexin1@cindasc.com caojialin@cindasc.com [Table_CoverAuthor] 唐爱金 医药行业首席分析师 贺鑫 医药行业联席首席分析师 曹佳琳 医药行业分析师 深耕血液净化黄金赛道，内生外延构建长期成长曲线 [Table_CoverStock] —天益医疗(301097)公司深度报告 [Table_ReportDate] 2026 年 1 月 27 日 证券研究报告 公司研究 [Table_ReportType] 公司深度报告 [Table_StockAndRank] 天益医疗(301097) 投资评级 买入 上次评级 [Table_Chart] -50% 0% 50% 100% 25/01 25/05 25/09 天益医疗 沪深300 资料来源：聚源，信达证券研发中心 [Table_BaseData] 公司主要数据 [Table_Summary] 核心逻辑：天益医疗作为国内领先的血液净化耗材制造商，通过战略性并购 补齐 CRRT 全 ...